Novo Nordisk and Photys Therapeutics Collaborate on Novel Proximity-Based Therapeutics for Cardiometabolic Diseases

Collaboration Announcement:
Photys Therapeutics, a proximity-based therapeutics company, has entered into a multi-year collaboration and license agreement with Novo Nordisk to develop novel proximity-based therapeutics for cardiometabolic diseases1 3.

Technology Integration:
The collaboration combines Novo Nordisk's expertise in cardiometabolic diseases with Photys' proprietary PHICS (PHosphorylation Inducing Chimeric Small molecules) technology, which induces proximity between a kinase and a target of interest to phosphorylate the target and alter its biologic function1 3.

Financial Terms:
The deal includes up to $186 million in upfront, development, and commercial milestone payments, as well as tiered royalties on annual net sales of licensed products5.

Strategic Alignment:
This collaboration aligns with Novo Nordisk's strategy to leverage external innovation and cutting-edge technology to advance new treatment options for cardiometabolic diseases2 4.

Potential Impact:
The partnership aims to develop transformative therapies that could make a significant impact for people living with cardiometabolic diseases, such as obesity and metabolic disorders2 4.